Soquelitinib for Hidradenitis Suppurativa

This trial tests a new treatment called Soquelitinib for individuals with hidradenitis suppurativa, a skin condition that causes painful lumps. The goal is to determine if Soquelitinib is safe and effective for those with moderate to severe symptoms. Participants will take tablets twice daily for 84 days. This trial may suit adults who have experienced moderate-to-severe hidradenitis suppurativa for over a year, frequently have painful lumps in at least two body areas, and have not responded well to antibiotics. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects on people.

Research has shown that Soquelitinib remains in the early testing phase, specifically Phase 1 trials. This phase primarily assesses the treatment's safety for humans. Currently, detailed safety information is limited, but the goal is to evaluate how well people tolerate the treatment and identify any side effects. Since Soquelitinib lacks approval for other uses, past studies provide little information about its safety. Participants in this trial will help researchers gather crucial data on its safety and potential side effects.

Most treatments for hidradenitis suppurativa involve antibiotics or biologics that aim to reduce inflammation and control symptoms. Soquelitinib is unique because it introduces a novel mechanism of action, potentially offering a new way to target the underlying causes of the condition. Researchers are excited about Soquelitinib because it might provide relief for patients who haven't responded well to existing therapies, and it is administered orally, which could be more convenient than some current options like injections or infusions. This fresh approach could pave the way for more effective and accessible treatment for those suffering from this challenging skin condition.

Research has shown that soquelitinib yields promising results for skin conditions. In earlier studies on atopic dermatitis, 75% of patients experienced significant improvement, compared to only 20% who received a placebo (a pill with no active medicine). This trial will evaluate soquelitinib for hidradenitis suppurativa, although specific data for this condition is not yet available. The drug's safety profile is similar to other treatments like JAK inhibitors or biologics, indicating it is generally well-tolerated. These findings offer hope that soquelitinib could also be effective for hidradenitis suppurativa.¹²³⁴⁵